[CITATION][C] Oliver Sartor talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler about FDA approval of PSMA
On December 1, the US Food and Drug Administration (FDA) approved 68Ga-PSMA-11 for
PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with …
PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with …
A Practical Guide to the Pearls and Pitfalls of PSMA PET Imaging
Prostate-specific membrane antigen (PSMA)-targeted PET agents have revolutionized the
care of patients with prostate cancer, supplanting traditional methods of imaging prostate …
care of patients with prostate cancer, supplanting traditional methods of imaging prostate …
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting
Abstract Introduction The Prostate Cancer Foundation (PCF) convened a PCF prostate‐
specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 …
specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 …
Updates to appropriate use criteria for PSMA PET
(AUC) for Prostate-Specific Membrane Antigen (PSMA) PET document has been updated
(1). This is due to the recent US Food and Drug Administration (FDA) approval of 177Lu …
(1). This is due to the recent US Food and Drug Administration (FDA) approval of 177Lu …
Theragnostics in prostate cancer.
A Farolfi, R Mei, S Ali, P Castellucci - … ),[and] Section of the Society of …, 2021 - europepmc.org
Prostate-specific membrane antigen (PSMA) is a molecular target for both imaging
diagnostics and therapeutics, ie, a theragnostics target. There has been a growing body of …
diagnostics and therapeutics, ie, a theragnostics target. There has been a growing body of …
68Ga-PSMA-11 NDA approval: a novel and successful academic partnership
G Carlucci, R Ippisch, R Slavik, A Mishoe… - Journal of Nuclear …, 2021 - Soc Nuclear Med
The University of California Los Angeles (UCLA) and University of California San Francisco
(UCSF) codeveloped 68Ga-PSMA-11 by conducting a bicentric pivotal phase 3 clinical trial …
(UCSF) codeveloped 68Ga-PSMA-11 by conducting a bicentric pivotal phase 3 clinical trial …
[HTML][HTML] PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies
Beginning in 2012,[18F]-and [68Ga]-labeled inhibitors of prostate-specific membrane
antigen (PSMA) entered early clinical development for positron emission tomography (PET) …
antigen (PSMA) entered early clinical development for positron emission tomography (PET) …
PSMA PET in prostate cancer
H Jadvar - Journal of Nuclear Medicine, 2015 - Soc Nuclear Med
Molecular imaging with PET using an increasing list of biologically relevant radiotracers is
paving the way for precision and personalized medicine in prostate cancer (1). Prostate …
paving the way for precision and personalized medicine in prostate cancer (1). Prostate …
[HTML][HTML] Prostate specific membrane antigen (PSMA) imaging: the past is prologue
PL Choyke, K Bouchelouche - Translational andrology and urology, 2019 - ncbi.nlm.nih.gov
PSMA 617, another agent developed later, was a minimal modification of this which allowed
binding of 177Lu-177 and 225Ac for targeted radionuclide treatment (9). These agents …
binding of 177Lu-177 and 225Ac for targeted radionuclide treatment (9). These agents …
An 89Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients
F Dietlein, C Kobe, SM Vázquez, T Fischer… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The short half-life of existing prostate-specific membrane antigen (PSMA) tracers limits their
time for internalization into tumor cells after injection, which is an essential prerequisite for …
time for internalization into tumor cells after injection, which is an essential prerequisite for …